Search for: "Bristol-Meyers Squibb Co"
Results 1 - 20
of 42
Sorted by Relevance
|
Sort by Date
3 Apr 2012, 1:00 am
The USPTO has filed a motion requesting reconsideration in Bristol Meyers Squibb Co. v. [read post]
20 Oct 2014, 10:00 pm
On October 20, 2014, the Federal Circuit issued an order denying the petition for rehearing or rehearing en banc filed in Bristol-Meyers Squibb Co. v. [read post]
4 Apr 2020, 8:25 pm
Karen Cochran of Shell Oil Co., Henry Hadad of Bristol-Meyers Squibb Co., Mike Ray of Sterne Kessler Goldstein Fox, and Todd Walters of Buchanan Ingersoll & Rooney PC will address the following questions concerning the management of a corporate IP department or IP practice during a crisis: • How can the you continue supporting clients' innovation when significant numbers of employees are teleworking and many are without childcare? [read post]
27 Nov 2022, 8:10 pm
.; Stephanie Donahue of Sanofi; Henry Hadad of Bristol-Meyers Squibb Co.; and Stuart Watt of Amgen, Inc. that will discuss the issues and arguments concerning the current state of enablement and written description law and where the law may be headed. [read post]
13 Sep 2018, 6:00 am
While the opinion carefully reviews a string of such cases ending with Bristol-Meyers Squibb Co. v. [read post]
20 Mar 2021, 8:45 pm
Brian Brookey of Tucker Ellis LLP; Serena Farquharson-Torres of Bristol-Meyers Squibb; Gloria Fuentes of Merck & Co. [read post]
31 Jan 2015, 8:47 pm
The drug is marketed in Australia by Bristol-Meyers Squibb (BMS) as ABILIFY, under license from the patentee Otsuka Pharmaceutical Co., Ltd.The Full Court has upheld the earlier finding of a single judge of the court that the patent is valid, notwithstanding that there is prior art teaching which, if carried out in a particular manner, could result in the claimed product. [read post]
8 Mar 2016, 8:01 am
Nicholas Meyer recently filed against Bristol-Myers Squibb and Otsuka Pharmaceutical Co. in the U.S. [read post]
12 Apr 2016, 10:57 am
Nicholas Meyer recently filed against Bristol-Myers Squibb and Otsuka Pharmaceutical Co. in the U.S. [read post]
7 Sep 2009, 12:06 pm
Eighteen months after the auction rate securities markets collapsed when Wall Street withdrew its support, companies like Bristol-Myers Squibb Co., Texas Instruments, Corning, and Teva Pharmaceuticals are still suffering from the Wall Street debacle. [read post]
20 Jul 2017, 7:44 am
Onglyza was co-developed by Bristol-Meyers Squibb and AstraZeneca and is a DPP-4 inhibitor. [read post]
10 Apr 2015, 3:00 am
West Virginia ex rel McGraw v Bristol Myers Squibb Co., 2014 WL 793569 (D.N.J. [read post]
31 Mar 2020, 1:27 pm
In so holding, the court determined that the Supreme Court’s ruling in a mass tort action, Bristol-Myers Squibb Co. v. [read post]
28 Mar 2012, 1:31 am
This time the drug in question is ‘atypical’ antipsychotic aripiprazole, marketed by Bristol-Meyers Squibb (BMS) as ABILIFY, under license from the patentee Otsuka Pharmaceutical Co., Ltd. [read post]
9 Mar 2011, 11:14 am
Bristol-Meyers Squibb Co., 156 N.J. 455, 463 (1998) (quoting N.J.R.E. 803(b)(4)). [read post]
25 Jun 2017, 10:42 pm
” Bristol-Meyers Squibb Co. v. [read post]
6 Jan 2020, 3:13 pm
” (Bristol- Myers Squibb Co. v. [read post]
27 Jun 2018, 1:16 am
Additionally the court asks whether the principles in the cases Bristol-Meyers Squibb and Boehringer Ingelheim apply without restrictions to parallel imports of medical devices.When it comes to repackaging of goods, the Court emphasised that any repackaging done by a third party without the proprietor's consent could create a risk in terms of the guarantee of origin of the goods. [read post]
27 Jun 2018, 1:16 am
Additionally the court asks whether the principles in the cases Bristol-Meyers Squibb and Boehringer Ingelheim apply without restrictions to parallel imports of medical devices.When it comes to repackaging of goods, the Court emphasised that any repackaging done by a third party without the proprietor's consent could create a risk in terms of the guarantee of origin of the goods. [read post]
12 Mar 2012, 5:41 pm
Bristol-Meyers Squibb Co. and Otsuka America Pharmaceutical, Inc., No. 12-cv-01124 (E.D.N.Y., Mar. 7, 2012) (Complaint) [read post]
